ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublications en collaboration avec des chercheurs de Memorial Sloan Kettering Cancer Center (10)
2024
-
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 695-702
2023
-
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036
2022
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670
2021
-
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677
-
Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2020
-
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218
2011
-
Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
Cancer and Metastasis Reviews, Vol. 30, Núm. SUPPL. 1
2004
-
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
Journal of Clinical Oncology, Vol. 22, Núm. 8, pp. 1480-1490
2002
-
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors
Oncologist, Vol. 7, Núm. 6, pp. 531-538
-
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity
Cancer Chemotherapy and Pharmacology, Vol. 50, Núm. 4, pp. 309-319